On the power of T-cells, with Cedrik Britten

In a new pharmaphorum podcast, web editor Nicole Raleigh sat down with Dr Cedrik Britten, chief medical officer at Immatics, to discuss novel PRAME-directed T-cell immunotherapies. Targeting PRAME unlocks new treatment options for a broad patient population with significant unmet medical need. And to do so safely and effectively requires deep expertise in immunology, drug development, and beyond. Britten explains how finding the right cancer target is only half the equation – the other half is creating the key that fits the lock to that cancer. So it is that, in addition to discovery of tumour-specific targets like PRAME, Immatics designs either engineered T-cell receptors (or TCRs) or bispecific molecules that recognise and bind to those targets. Britten also shares his dreams for the future of the field; his hopes far into the distant horizon. You can listen to episode 259 of the pharmaphorum podcast in the player below, download the episode to your computer, or find it – and subscribe to the rest of the series – on Apple Podcasts, Spotify, Overcast, Pocket Casts, Podbean, and pretty much wherever else you download your other podcasts from.